Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.34 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.33 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.33 |
| ▸ | CACNA1G known ✓ | O43497 | 1/20 | 0.33 |
| ▸ | CACNA1H known ✓ | O95180 | 1/20 | 0.33 |
| ▸ | CACNA1I known ✓ | Q9P0X4 | 1/20 | 0.33 |
| ▸ | HTR6 known ✓ | P50406 | 3/20 | 0.33 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.33 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.33 |
| ▸ | HTR7 known ✓ | P34969 | 2/20 | 0.33 |
| ▸ | FABP4 | P15090 | 2/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.34 |
| ▸ | FABP3 | P05413 | 1/20 | 0.34 |
| ▸ | PDE1A | P54750 | 4/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.33 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1738012 | 0.99 | FABP4 (0.35) | FABP4DPP4PLA2G2AFABP3PDE1A | |
| Hydrochloric Acid SCHEMBL1737036 | 0.94 | HTR6 (0.35) | FABP4DPP4PLA2G2APDE1APDE1B | |
| Hydrochloric Acid SCHEMBL1736873 | 0.93 | HTR6 (0.34) | FABP4DPP4PLA2G2APDE1APDE1B | |
| SCHEMBL1737566 | 0.93 | HTR6 (0.35) | FABP4DPP4PLA2G2APDE1APDE1B | |
| SCHEMBL1736043 | 0.92 | HTR6 (0.35) | FABP4DPP4PLA2G2APDE1APDE1B | |
| Hydrochloric Acid SCHEMBL1737690 | 0.91 | HTR2A (0.34) | FABP4DPP4PLA2G2APDE1APDE1B | |
| Hydrochloric Acid SCHEMBL1737152 | 0.90 | FABP4 (0.41) | FABP4MEN1ALDH1A1KMT2AHSD17B10 | |
| Hydrochloric Acid SCHEMBL1737491 | 0.90 | HTR6 (0.34) | FABP4DPP4PLA2G2APDE1APDE1B | |
| SCHEMBL1737624 | 0.90 | HTR2A (0.35) | FABP4DPP4PLA2G2APDE1APDE1B | |
| SCHEMBL1737790 | 0.89 | FABP4 (0.42) | FABP4MEN1ALDH1A1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190070159-A1 | NOVEL PHARMACEUTICAL USES | TAKEDA PHARMACEUTICALS CO (JP) | 2019-03-07 | — | — | US | claimed |
| US-20180085361-A1 | NOVEL PHARMACEUTICAL USES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-29 | — | — | US | claimed |
| EP-1784404-B1 | PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORP (KR) | 2011-11-16 | — | — | EP | claimed |
| US-20110263306-A1 | COMPUTER SYSTEM AND PROGRAM | NAMCO BANDAI GAMES INC. (JP) | 2011-10-27 | — | — | US | claimed |
| US-7662832-B2 | Pyrrolo[2,3-c]pyridine derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2010-02-16 | — | — | US | claimed |
| EP-1784404-A4 | PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORP (KR) | 2009-09-09 | — | — | EP | claimed |
| JP-2008511621-A | — | — | 2008-04-17 | — | — | JP | claimed |
| US-20070219230-A1 | PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2007-09-20 | — | — | US | claimed |
| EP-1784404-A1 | PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Yuhan Corporation (KR) | 2007-05-16 | — | — | EP | claimed |
| WO-2006025716-A1 | PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2006-03-09 | — | — | WO | claimed |
| US-20190070159-A1 | NOVEL PHARMACEUTICAL USES | TAKEDA PHARMACEUTICALS CO (JP) | 2019-03-07 | — | — | US | disclosed |
| US-20180085361-A1 | NOVEL PHARMACEUTICAL USES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-29 | — | — | US | disclosed |
| EP-3277279-A1 | NOVEL PHARMACEUTICAL USES | Takeda Pharmaceutical Company Limited (JP) | 2018-02-07 | — | — | EP | disclosed |
| WO-2016159386-A1 | NOVEL PHARMACEUTICAL USES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-06 | — | — | WO | disclosed |
| US-8188114-B2 | Pyrrolo[2,3-C]pyridine derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2012-05-29 | — | — | US | disclosed |
| EP-1784404-B1 | PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORP (KR) | 2011-11-16 | — | — | EP | disclosed |
| US-20110263306-A1 | COMPUTER SYSTEM AND PROGRAM | NAMCO BANDAI GAMES INC. (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20100069430-A1 | PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2010-03-18 | — | — | US | disclosed |
| US-7662832-B2 | Pyrrolo[2,3-c]pyridine derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2010-02-16 | — | — | US | disclosed |
| US-20070219230-A1 | PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069430-A1 | PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | PGA5, ATP6AP1, ATP6V1H | DPP4 373/4885HTR2A 1492/4885HTR2C 599/4885 |
| US-20070219230-A1 | PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | PGA5, ATP6AP1, ATP6V1H | DPP4 373/4885HTR2A 1492/4885HTR2C 599/4885 |
| US-20190070159-A1 | NOVEL PHARMACEUTICAL USES | ATP1A4, HRH2, ATP4A | DPP4 187/4885HTR2A 2461/4885HTR2C 1800/4885 |
| US-20180085361-A1 | NOVEL PHARMACEUTICAL USES | ATP1A4, HRH2, ATP4A | DPP4 187/4885HTR2A 2461/4885HTR2C 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.